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Abstract
Background: The use of most anti-malarial medications is restricted during pregnancy, but two
doses of sulphadoxine-pyrimethamine are recommended after the first trimester as intermittent
preventive treatment in pregnancy (IPTp). In The Gambia, only 32% of women receive two doses
and very little research has been conducted on women's awareness of drug safety during
pregnancy. The objective of this paper was to assess whether rural Gambian women were aware
of the importance of the timing of the two-dose IPT dose schedule and its relevance to drug safety.
Methods: This was a qualitative study in which 41 interviews and 16 focus group discussions with
women, adolescents, men and traditional birth attendants were conducted. A generic qualitative
approach was used to generate a theory as to why women might not participate in IPTp as
recommended.
Results: Although most women used calendar months to count their stage of pregnancy, these
months did not correlate with their concept of foetal development. Foetal growth was described
following Islamic tradition as water, clot, piece of meat and human being, although there was little
consensus about the order or timing in which these stages occurred. Common signs and conditions
of malaria were known. Women were anxious about miscarriage and recognized that some
medicines should not be taken in the first trimester, but were urged by men and traditional birth
attendants to attend for antenatal care in the first trimester to "start treatment." General
knowledge about the purpose of pregnancy medications and when they should be taken was poor
among both men and women. One important result was that women relied entirely on health
workers to provide safe drugs, at the correct time.
Conclusion: Women did not have relevant information to judge the safety and appropriate timing
of pregnancy drugs, which made them over-reliant on health workers. They should be encouraged
to date their own pregnancies in culturally relevant terms and to anticipate when and which
medications they should receive.
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Background
Many anti-malarial drugs have not been licensed for use
in pregnancy because their risk has not been assessed in
controlled trials and some are potentially embryotoxic
[1]. In most African countries, including The Gambia, sul-
phadoxine-pyrimethamine (SP) is recommended during
the second and third trimesters of pregnancy for intermit-
tent preventive treatment (IPT) in areas of moderate to
high malaria transmission [2]. SP has a favourable safety
profile during pregnancy despite some concerns about
severe cutaneous reactions and teratogenesis, although it
is not recommended for HIV-positive women on cotri-
moxazole prophylaxis for whom there is a higher risk of
severe adverse reactions [3]. Use of anti-folate agents like
SP is also contra-indicated in the first trimester because of
the risk of neural tube defects. A postulated association
between SP and kernicterus has not been observed in
practice. The risks of malaria to mother and foetus are
judged to outweigh potential risks of SP toxicity, and pol-
icies and protocols governing its use are intended to pro-
tect pregnant women and their babies from IPTp exposure
in the first trimester [2].
Despite this, without good training and close supervision
of health care workers, there is a risk that women will be
treated incorrectly. In the absence of pregnancy registers,
the size of this risk is still largely unknown [4]. Nor has
there been much research on women's awareness of drug
safety issues in early pregnancy. Inadvertent exposure to
drugs that are contra-indicated in early pregnancy could
arise if women were unaware of, or failed to disclose their
pregnancies. This hypothesis was investigated qualita-
tively among Gambian rural women in an earlier publica-
tion, in which it was reported that women consciously
sought to hide their pregnancies as a way of retaining
some control in their lives and avoiding malign gossip [5].
This resulted in delayed attendance for antenatal care
(ANC). For the same reason, women with clinical malaria
sometimes chose not to disclose an early pregnancy when
seeking out-patient treatment. As health workers in out-
patient clinics frequently failed to inquire about preg-
nancy, this potentially exposed women to the risk of being
given medications that might have been contra-indicated
[5].
In general, ANC is the main route for obtaining IPTp and
late ANC attendance is one of the most common reasons
given to account for low IPT coverage [6]. Another is that
women attend ANC during the first trimester, when they
cannot be treated and do not return for their first IPTp
dose at the recommended time (between 14 and 34
weeks) [7]. Failure to return suggests that women may not
appreciate the importance of the timely administration of
IPTp and are not pro-active in requesting it. In the Gam-
bia, 98% of women attend ANC at least once during preg-
nancy [8], a half visit at least four times and about 25%
first present before 20 weeks [9]. Despite this high level of
contact with health facilities and the provision of free
IPTp, coverage for two IPTp doses among women aged
15–49 was reported to be just 32%, with little difference
between urban and rural areas or in relation to education
or wealth indices [8]. In view of this low coverage, data
from the earlier study on pregnancy disclosure has been
analysed to assess women's awareness of the need for
timely IPTp and is reported in this paper.
Methods
Ethical approval was obtained from the University of
Manchester's Committee on the Ethics of Research on
Human Beings and the Gambian Government/Medical
Research Council (MRC) Joint Ethics Committee.
Participants and study area
As previously described [5] the study was conducted
between February and November 2007 in rural Kiang
West, The Gambia, and participants were mainly Muslim
and belonged to the Mandinka tribal group. The research
took place in three villages (Jiffarong, Dumbuto and Jan-
neh Kunda) that were eight, 30 and 40 kilometres away
from the UK Medical Research Council (MRC) field sta-
tion at Keneba. Training interviews were undertaken in
nearby Manduar. ANC in each village was provided by
MRC/government trekking teams, assisted by MRC
Keneba midwifery and medical staff. Coverage of ANC by
skilled personnel (doctor, nurse, or midwife) is relatively
high in The Gambia and about half of the female popula-
tion delivers in a health facility [8]. Standard of Practice
Guidelines used in West Kiang at the time of the study
instructed nurses/midwives to offer at least two doses of
SP during pregnancy and advised that SP was considered
safe between 14–34 weeks but should not be given in the
first trimester or after 34 weeks. The recommended dose
was three tablets, with the 1st dose at 18–28 weeks and the
2nd dose at 30–34 weeks, with doses spaced four weeks
apart, to be taken under direct observation. The instruc-
tions were also to screen pregnant women at prenatal vis-
its for fever or other symptoms of malaria, to make a thick
film if symptomatic, then to treat with SP and chloro-
quine. Otherwise nurses/midwives were to encourage
women to use insecticide-treated bed nets and take other
measures to avoid mosquito bites. To prevent anaemia all
women were given daily supplementation tablets of com-
bined iron and folate. Other drugs routinely used were
paracetamol, methyldopa, diazepam, amoxicillin/ampi-
cillin and metronidazole.
Using a list generated from the MRC database, nulliparous
and parous women were consecutively approached for
either in-depth interviews or focus group discussions
(FGDs). Men who were regarded as senior in terms of vil-Malaria Journal 2009, 8:25 http://www.malariajournal.com/content/8/1/25
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lage authority or who practiced polygyny were recruited
by community health workers, as were traditional birth
attendants (TBAs). Women who were participating in a
MRC micronutrient trial were excluded to avoid any con-
cerns about their supplementation. The consent of the
alkalo (village head) was sought to approach individuals
living in the village. Individual participants gave written
(signature or thumb print) consent. Four FGDs were held
with younger married women, four with older married
women, three with adolescent girls, one with traditional
birth attendants and four with men (16 in total). A total
of 41 in-depth interviews were conducted.
Interviews
Audio-taped interviews and FGDs with women were con-
ducted by a Gambian nursing-assistant (ID), and those
with men by a male field worker. The sessions took place
in a health centre or a village compound in which privacy
could be maintained. Observations about malaria in preg-
nancy and the use of anti-malarials were recorded within
a topic guide that covered broader pregnancy issues, but
included women's use of medication during pregnancy.
All interviews were attended by ES, and ID was trained not
to ask questions that would make women anxious about
drugs (eg foetal abnormalities). During training, ques-
tions were asked in English and translated into Mandinka
to monitor the interview content, but once the quality of
interviewing was satisfactory, interviews were conducted
solely in Mandinka. ES and ID reviewed each session, lis-
tening to the tapes, which ID translated. This allowed ES
to provide feedback and to identify emerging topics to be
explored in later interviews. The transcripts were sent to a
Gambian commercial company for formal translation.
Those judged to be of unsatisfactory quality were returned
for re-translation.
Data analysis
Transcripts were read independently by ES and LB. A
generic qualitative approach was used [10]. The theoreti-
cal position was derived from medical ethics, which
informed the research topics (e.g. reasons why women
remained unaware of the significance of the IPTp sched-
ule), and led to a theory as to why women might not
receive IPTp as recommended. Actions that influenced
IPTp treatment were systematically coded in an iterative
process that allowed categorisation of sub-themes. Inter-
views, FGDs and subgroup data were compared and
repeated and discordant themes identified. The process
continued until both researchers were satisfied with the
explanatory process. In this report, combined data from
FGDs and interviews are presented and main themes illus-
trated by verbatim quotations translated from Mandinka
to English.
Results
Measuring stage of pregnancy
When asked how they measured their pregnancy, most
women said "by moon" and/or calendar months. They and
their husbands monitored their menstrual cycle because
they were not allowed to sleep with their husbands, pray
or do other household tasks when menstruating. A men's
focus group identified one of the problems of identifying
stage of pregnancy when relying on calendar months:
"There are some women who will see their period at the begin-
ning of the month, others will see it around day fifteen, others
will have it around day twenty five .... In a case where preg-
nancy reduces (ie the period occurs early in the month),
some women may go up to 10 or 11 months before they
deliver." [JKMFG-4].
Stages of foetal growth
Foetal growth was described following Islamic tradition as
water, clot, piece of meat and human being. These stages
were recognized by all men and women of different ages.
Men were more consistent about the order of these events
but not their timing. Among women there was little con-
sensus about the timing or order in which these stages
occurred (Table 1, a-d), and as an understanding of basic
embryology was not part of TBA training, their views were
similar to those of other older women. Adolescent girls
were particularly vague about foetal growth stages.
"Quickening" or the first movement of the foetus, which
health workers partly relied on as an indicator for giving
the first IPTp dose, was not consistently associated with
any particular stage of pregnancy by women. The baby
was described as kicking or "shaking" at various times after
three months (Table 1, a-d). Generally the foetus was not
regarded as human before the fourth month.
Effects of malaria on the foetus
Men and women were able to list the common signs of
malaria such as shivering, fever, vomiting, joint pain, gen-
eral body weakness. They knew it caused anaemia and
pre-term birth and that bed nets offered protection. They
had some idea of the mechanisms by which malaria
caused illness in a pregnant woman and foetus. One man,
recounting how his brother-in-law's pregnant wife had to
go to hospital with malaria, had been told that malaria
reduced the blood by 60%, but was puzzled and asked
"How can that be possible?" My brother in-law said different
parts of the body start pulling against each other, and that
affects the blood." [JKMFG-3]
Malaria was considered to affect the foetus indirectly.
When young women were asked, "Do foetuses get sick in the
womb?", one replied "Yes, it gets sick. It may be that it does
not have the parasites but if the mother is not eating good food,
that can make it get ill." [MYWFG-1]Malaria Journal 2009, 8:25 http://www.malariajournal.com/content/8/1/25
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Table 1: Description of stages of foetal growth by different groups
MONTH YOUNG WOMEN 1a OLDER WOMEN 1b
"Oh, I don't have any idea about that." (JKW1-1)
1 "It looks like a piece of meat." (DYWI-6) "It is in the semen stage" (JKOWFG-1)
"It will remain water for one month before it will turn into blood." 
(MOWFG-1)
"It is just like water." (JKOWI-6)
2 "It has a grey colour."(DYWI-6) "It is in a liquid stage" (JKOWFG-1)
"It appears like a clot." (JKOWI-6)
3 "It looks like a lizard."(DYWI-6)
"It looks like pus....The baby is kicking on one side...It moves 
but the movement is not powerful." (DYW1-2)
"It is in a blood-like state." (DYWI-4)
"It is in a clot form." (JKOWFG-1) (JKOWI-2)
"If the foetus is a female, it looks like a tortoise. If it is a male, it looks 
like a lizard." (JKOWFG-1)
4 "It is nearly mature"(DYWI-6)
"Limbs form" (JKYWI-4)
"From 4–6 months it kicks from all directions" (DYW1-2)
"It starts kicking at four months" (JKOWFG-1)
"At four months it will no longer be blood or a piece of meat. It will be 
a human being. You will know whether the baby will be a boy or a girl." 
(MOWFG-1)
"At four months it is just like a bulk of blood." (JKOWI-2)
"Limbs will start to appear." (JKOWI-6)
5 "I think it stays like that until 5–7 months. Then God breaks it 
into two pieces and reconstructs it again"(DYWI-6)
"From five to six months, all features of a human being are 
developed.....but nine months is the time that the baby is fully 
matured." (JKYWI-4)
"When the baby has been five months in the stomach, the stomach will 
shake." (MOWFG-1)
6 "It looks like a piece of meat."(JKYWI-4) "Within six months the baby is close to a human being." (JKOWFG-1) 
(JKOWI-2)
"At six months the stomach will shake again" (MOWFG-1)
8 "It is fully matured in all aspects"(DYWI-6) "At eight or nine months the stomach will shake and you will know 
that God's time has come for you to deliver." (MOWFG-1)
9 "It is now a complete human being. At this stage, if you feel 
hungry, you see the baby start moving"(DYWI-6)
MONTH ADOLESCENTS 1c MEN 1d
"Pregnancy is never steady.. it has stages, from semen to blood clot, 
until it departs from there, that will equal to 120 days." (JKMFG-4)
1 "It looks like a piece of meat" (DAFG-1)
"It appears like a blood clot" (JAFG-3)
"The pregnancy is just semen" (JJMFG-1)
"At 7 days, pregnancy is a clot" (JKMFG-3)
2 "Clot" (DAFG-1) "Blood clot" (JJMFG-1)
"It begins to have human shape." (JKMFG-3)
3 "I don't know." (DAFG-1)
"It then looks like a small frog" (JAFG-3)
"It is not at a human stage, it is like blood." (JKMFG-3)
4 "By then it is an egg." (DAFG-1) "The blood clot becomes firm." (JJMFG-1)
"I cannot tell you anything about that". I heard women saying that 
there is movement at four months, but I don't know.(JKMFG-2)
"At four months, things come together." (JKMFG-3)
5 "It is about to become a human being." (DAFG-1) "A piece of meat" (JJMFG-1)
"Limbs are forming" (JKMFG-3)
"At this stage it is now human." (JKMFG-3)Malaria Journal 2009, 8:25 http://www.malariajournal.com/content/8/1/25
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Perceived safety of medications during pregnancy
Women were able to understand the concept that some
drugs were contra-indicated early in pregnancy. There was
general agreement that a local herb (jambakasala)
"cleaned the baby" in utero and was safe even in the first
month of pregnancy unlike another herbal remedy (kati-
jangkumou) which could not be taken till later. Women
named chloroquine/nivaquine as a western drug to be
avoided during the first trimester because it was bitter, a
characteristic associated with abortifacients. Some of the
men thought that paracetamol also caused abortion.
TBAs actively encouraged women to go to ANC in the first
trimester, "because doctors like that, so that she (the mother)
can start treatment." [DTBAI-1] Men uniformly advised
along similar lines, noting "You should start taking your
medication at one to two or three months. That way they
(health workers) can help you." [JKMFG-4] Despite this
injunction, men had very little knowledge of the drugs
given to women, other than describing their colour, and
some idea that red ones were for blood. One said,
"My advice is to go to the clinic to see a nurse. Those people will
tell her what to do and they will give her some medication."
[JKMFG-3].
A similar view was as follows:
"Well, as human being we take those drugs with the hope that
they are useful. I don't think if they are useless, the woman will
have any cause to take them" [JJMFG].
Women were equally unclear about the drugs they were
given and accepted their safety if given by a nurse or doc-
tor at ANC. One group of TBAs thought that women were
given "an injection for Jarrara "(cerebral malaria)
[JOLITBA-1], which presumably was the routine tetanus
toxoid vaccination. When asked "What are the medicines
for?" typical replies were:"I don't know, but they said if I take
them, my dizziness and shaking will go away" [JKYWI-3] and
"The red tablet is for blood increase. The white tablet is for good
health and the yellow tablet also serves the same purpose –
strength and good health." [JKYWI-4]
Knowledge of IPTp dosing schedules
The fact that malaria causes anaemia and that iron pre-
vents anaemia led to some confusion about the difference
between anti-malarial and iron treatments. When asked
about the month when IPTp was first given, one comment
was as follows:
"On one occasion I was at four months, some other occasions,
if I bought a ticket (for ANC registration) and I had normal
health, they wouldn't give it to me. But as time went on, they
would check my blood to see whether it was going up or down.
Then they would start giving it to me." [JK0WFG-1 Women's
reports of how many doses of IPTp they had received were
unreliable. Some older women claimed they had received
as many as five doses. [JKOWFG-1] Younger women gen-
erally knew that they should get two doses, but even this
was disputed, as shown in the following conversation:
"How many times do you take your malaria medication?"
"Three times"
"Me, twice"
"It was supposed to be three. If you take anti-malarial drugs
during the first three months, the effects of the drugs lessen the
severity even if you have parasites in your blood. The second
dose provides you longer protection. If you complete the third
dose, even if you have parasites in the blood, they will not harm
you." [MdYWFG-1]
Women consistently said they did not know when to take
IPTp.
"How did you know it is time for you to take the second dose?"
"I don't know. I went to the Health Centre. I was given it by
them when the time was right."
"Did you know, or have any idea when you should take the
anti-malarial drug?
"No idea." [JWYI-1]
6 "It starts moving" (DAFG-1) "Limbs are forming" (JKMFG-3)
"It is now a complete human being" (JKMFG-3)
7
8
9
"At seven months it is mature" (JKMFG-3)
"It starts having limbs" (JJMFG-1)
"At 7 months there is a soul in the body, but at 8 months the soul is 
suspended from the body. By 9 months it reunites with the body again" 
(JJMFG-1)
"It turns into a human being" (JAFG-3)
Table 1: Description of stages of foetal growth by different groups (Continued)Malaria Journal 2009, 8:25 http://www.malariajournal.com/content/8/1/25
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When asked how she knew it was right time for IPTp,
another said "When I came here for the first time they checked
me and I was given the first dose. Then I came for the second,
it was the same. I was given a second dose, but I cannot tell if
it was the right time." [JWYI-2]
Discussion
These results highlight a general ignorance of the impor-
tance or relevance of the IPTp schedule within this rural
Gambian population, which is likely to reflect, at least in
part, a paradigm of foetal development that was not based
on weeks or trimesters. It also reflected a very confused
understanding of the different drugs given to pregnant
women and lack of awareness that some (such as haema-
tinics), but not all medications, may be used safely in the
first trimester. The main consequence was that women
were entirely dependent on the ANC nurse to give IPTp
correctly, as women and their husbands firmly believed
that unsafe drugs would not be dispensed by health work-
ers. In other respects, this Gambian community was quite
well informed about the causes and effects of malaria,
which is perhaps not surprising given that the MRC has
conducted malaria studies in this country over many years
and malaria prevalence has declined following the com-
munity uptake of the various control strategies that have
been introduced [11]. This may also partly account for
general acceptance by the community that IPTp was safe,
although elsewhere, side effects have caused anxiety and
fears [12,13].
The results do not provide a comprehensive account of the
determinant of IPTp effectiveness as this study was not
specifically designed to investigate IPTp uptake. Ques-
tions on IPTp were asked because it was one of the most
common drugs to which women in this setting were
exposed, but use of anti-malarial drugs was only part of a
more detailed interview schedule encompassing preg-
nancy recognition and disclosure, and its potential conse-
quences for inadvertent drug exposure. Qualitative
research is also not generalisable but these results are rel-
evant for those working in other Islamic communities that
share similar concepts of foetal development [14]. Even
then, local variations based on autochthonous traditions
may be evident [15]. In Islam, the foetus is described as
progressing through a series of changes leading to
"ensoulment", when an angel breathes spirit into the foe-
tus at 120 days and it becomes a human being, with legal
rights [16,17]. Since women did not conceptualize their
pregnancies in weeks and trimesters, they may have had
difficulties in understanding the timing of IPTp. Some-
times women are asked about "quickening", understood
to mean the first maternally-detected movements of the
foetus, which typically occur around 18 weeks gestation.
However, women who conceptualize the foetus as a "clot"
may not relate to this indicator as expected. Some Nige-
rian research provided an example of how an educated
secondary school educated Yoruba mother had learnt to
correlate accurately her account of foetal development
based on Islamic concepts with calendar months [14].
This demonstrates that it should be feasible to teach
women to date their own pregnancies in culturally rele-
vant terms. As well as helping mothers to better under-
stand the physiology of pregnancy, it could be used to
inform women of the purpose and timing of IPTp, and to
explain why some drugs such as IPTp should be avoided,
especially in the first trimester. As in other cultures [18],
women partly understood this concept and avoided some
local and western medications during early pregnancy,
but this was not linked to any factual knowledge about
foetal growth and how some drugs can harm the develop-
ing foetus.
Women's reliance on health workers to administer drugs
correctly was understandable as women were accustomed
to obeying authority figures, but this practice carries risks
that could be reduced if they were better informed.
Although the situation has not been assessed in The Gam-
bia, erratic timing of IPTp doses has been identified as an
important issue in other countries [19]. In one Kenyan
study, only 15.7% of the women who had two IPTp doses
had received them at the correct time [6]. In Malawi, it was
reported that health workers were not adhering to exclu-
sion of first trimester pregnancies [18]. All women were
administered IPTp during their first clinic visit, irrespec-
tive of the week of pregnancy, which ranged from 10 to 36
weeks, and nearly a quarter of women said they were told
to take it in the first trimester. In Uganda 9% of women
also received IPTp in the first trimester [20]. The Gambian
women in the present study seemed unaware that IPTp
was contraindicated in the first trimester. Unlike chloro-
quine and some other bitter medicines, it was not sponta-
neously mentioned as a drug to avoid because of the risk
of miscarriage. A common factor shared by women in
most cultures is fear of an early pregnancy loss, which was
one of the reasons that Gambian women delayed ANC
attendance [5]. In Kenya, mothers who had experienced a
child death were significantly less likely to have received
SP and its use was associated with miscarriage [13]. There
is scope for a great deal of misunderstanding when
women do not comprehend why some drugs can be used
safely in later pregnancy, but not in the early stages. There
are similar issues around the number of recommended
doses. These Gambian women, like some Kenyans [13]
did not know how many IPTp doses they should receive.
Some women claimed to have been given multiple doses,
but this may have been because they confused malaria
and haematinics. In settings where monthly IPTp has
been recommended, this could lead to excessive dosing. A
median of five doses was administered in one study of
IPTp in HIV-positive women [21]. No adverse events inMalaria Journal 2009, 8:25 http://www.malariajournal.com/content/8/1/25
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mothers or newborns were observed, but as there was no
difference in pregnancy outcomes between HIV-negative
women who receive multiple, as opposed to two doses of
IPTp, higher frequency dosing had little to recommend it.
There are also reports of women receiving IPTp at an inter-
val of less than four weeks [6]. These risks remain as long
as women, and those who advise them (eg. their hus-
bands) are so confused about pregnancy medication.
Conclusion
This study has highlighted how important it is for women
to understand the stages of pregnancy, as well as which
drugs cannot be safely taken in early pregnancy and why.
Studies should be conducted to confirm that women have
made sense of this information and are confident in their
use of IPTp. This would go some way to helping them
avoid untimely administration of IPT and other medica-
tions. This process should run alongside health worker
training, which is essential, but only part of the solution
[22].
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